Liquidia Corporation Files Response To United Therapeutics Lawsuit And Files Counterclaims; Seeks Dismissal Of All Claims Related To '793 Patent Based On Prior Findings Of Invalidity Which Have Been Affirmed By The Federal Circuit
Portfolio Pulse from Benzinga Newsdesk
Liquidia Corporation has responded to a patent infringement lawsuit by United Therapeutics, seeking dismissal of all claims related to the '793 patent due to prior invalidity findings affirmed by the Federal Circuit. Liquidia also filed counterclaims asserting the '327 patent is not infringed, invalid, and unenforceable, alleging United Therapeutics failed to disclose prior art during patent prosecution. The dispute centers around Liquidia's NDA for YUTREPIA, an inhalation powder for treating pulmonary hypertension. Liquidia argues against a 30-month regulatory stay, as the patents were not issued before the original NDA filing.
January 08, 2024 | 1:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Liquidia Corporation is defending its NDA for YUTREPIA against United Therapeutics' patent claims, which could impact the drug's market entry and Liquidia's financial prospects.
Liquidia's aggressive defense and counterclaims against United Therapeutics' patents could, if successful, remove legal barriers to YUTREPIA's market entry, positively impacting Liquidia's stock in the short term due to the potential revenue from the new drug.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
United Therapeutics faces counterclaims from Liquidia Corporation, which could affect its patent holdings and competitive position in the pulmonary hypertension market.
The counterclaims by Liquidia, if successful, could invalidate or render unenforceable United Therapeutics' patents, potentially leading to increased competition and a negative impact on United Therapeutics' stock in the short term.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 80